Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
28 mars 2024 03h00 HE
|
Intravacc B.V.
Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine developmentIntravacc has IP and know-how in vaccine conjugation and manufacturing of carrier protein based...
Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2
26 mars 2024 03h00 HE
|
Intravacc B.V.
First in human phase I clinical study using OMV as an adjuvant for intranasal vaccinationAvacc 10® intranasal booster vaccine induces a mucosal response and no adverse eventsData will be presented at...
Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections
16 janv. 2024 06h00 HE
|
Intravacc B.V.
Intravacc secures $633K funding from CARB-X to develop a vaccine against or Neisseria gonorrhoeae.
Intravacc launches new website with a wealth of scientific knowledge to elevate vaccine innovation
20 déc. 2023 06h10 HE
|
Intravacc B.V.
Intravacc's new website offers an immersive user experience, showcasing their CDMO expertise vaccine platforms and a hub for scientific publications.
Intravacc announces publication of In Vitro alternative to replace animal pyrogen test for vaccines
19 sept. 2023 02h00 HE
|
Intravacc B.V.
Intravacc and Sanquin Diagnostic Services optimized the in vitro Monocyte Activation Test (MAT) for OMV vaccinesMAT test potential replacement for the traditional rabbit pyrogen testing (RPT) for...
Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention
14 sept. 2023 02h00 HE
|
Intravacc B.V.
Mucosal route induces both localized and systemic immunityIntravacc is currently developing 3 OMV-based intranasal vaccinesArticle published in peer-reviewed journal ‘Current Opinions in Immunology’ ...